Dual-specificity phosphatase 6 (DUSP6, mitogen-activated protein kinase (MAPK) phosphatase 3 or PYST1) dephosphorylates phosphotyrosine and phosphothreonine residues on extracellular signal-regulated kinase (ERK1/ 2; MAPK1/2) to inactivate the ERK1/2 kinase. DUSP6 is a critical regulator of the ERK signaling cascade and has been implicated as a tumor suppressor. We report here experimental evidences that DUSP6 is transcriptionally upregulated in primary and long-term cultures of human glioblastoma, as assayed by northern hybridization and real-time quantitative PCR, producing constitutive high level of protein expression. Functional assays were performed with adenovirus-mediated expression of DUSP6 in glioblastoma cultures. Protein overexpression inhibits growth by inducing G1-phase delay and increased mitogenic/anchorage dependence and clonogenic potential in vitro. Changes in cell morphology were associated with an increased tumor growth in vivo. Chemoresistance is a major cause of treatment failure and poor outcome in human glioblastomas. Importantly, DUSP6 overexpression increased resistance to cisplatinmediated cell death in vitro and in vivo. Antisense-mediated depletion of DUSP6 acted in lowering the threshold to anticancer DNA-damaging drugs. We conclude that upregulation of DUSP6 exerts a tumor-promoting role in human glioblastomas exacerbating the malignant phenotype.
Introduction
Dual-specificity phosphatases (DUSPs) negatively regulate mitogen-activated protein kinase (MAPK) signaling by dephosphorylating components of the MAPK cascade. DUSPs are typically negative feedback regulators of MAPK activity that become transcriptionally induced after stress or mitogenic stimulation; this leads to early production of proteins that inactivate MAPKs within 20-40 min (Owens and Keyse, 2007) . Importantly, some DUSPs may provide biomarkers of therapeutic responsiveness and patient outcome in specific cancers, as well as DUSP1 and DUSP2 in different type of cancers (reviewed in Patterson et al., 2009) .
DUSP6 is a cytoplasmic member of this family that has been implicated in the development of cancer. Pancreatic cancer cells progress towards a more aggressive and invasive phenotype, following loss of DUSP6 expression (Furukawa et al., 2003 (Furukawa et al., , 2005 . Overexpression of DUSP6 in estrogen receptor-positive breast cancer cells confers resistance to the growth inhibitory effects of tamoxifen (Cui et al., 2006) and its expression is strongly upregulated in HER2-positive breast tumors (Lucci et al., 2010) . Moreover, DUSP6 is part of a high-risk signature gene for non-small cell lung cancer (Chen et al., 2007) , and its expression is significantly correlated with high extracellular signalregulated kinase (ERK) 1/2 activity in primary human ovarian cancer cells (Chan et al., 2008) . Remarkably, in human glioblastoma cells DUSP6 gene was induced upon platelet-derived growth factor (PDGF) stimulation (Tullai et al., 2004) . Moreover, DUSP6 can be upregulated in specific cancers exhibiting aberrant receptor tyrosine kinase and Ras/Raf signaling, such as non-small cell lung cancer, potentially as a negative-feedback regulator of mitogenic signaling (Sato et al., 2006) .
Although the DUSP6 gene is a potential tumorsuppressor in some cancers (Furukawa et al., 2003 (Furukawa et al., , 2005 Okudela et al., 2009; Zhang et al., 2010) , here, we show that DUSP6 exerts tumor-promoting properties in glioblastoma cancers. Recently, some papers report that upregulation of tumor suppressor genes might promote the malignant phenotype of cancer cells (Hong et al., 2007) . This split of personality was recently documented for PTEN and IDH1 genes in glioblastoma cancers (Li et al., 2008; Yan et al., 2009) . Indeed, particular DUSPs may have contradicting roles in different tumor types, such as DUSP1, that increased or decreased its expression in different type of cancers, depending on the stage of carcinogenesis (reviewed in Patterson et al., 2009) .
Glioblastoma multiforme is the most aggressive and frequent subtype of glioma, and shows very little response to chemotherapy (Maher et al., 2001) . Recently, members of the DUSP family, such as DUSP26 and DUSP4, have been involved in determining the malignant phenotype of glioblastomas (Tanuma et al., 2009; Waha et al., 2010) .
We report here experimental evidence that DUSP6 is transcriptionally upregulated in primary and long-term cultures of human glioblastoma, producing constitutive high level of protein expression. Functional assays were performed with adenovirus-mediated expression of DUSP6 in glioblastoma cultures. Protein overexpression inhibits growth by inducing G1-phase delay and inducing cell flattening that was associated with an increased tumor growth in vivo and inhibition of epidermal growth factor (EGF)-detachment in vitro. Finally, DUSP6 overexpression decreases tumor cell sensitivity to anticancer DNA-damaging cisplatin, indicating that DUSP6 may function as a tumor promoter in these cancers.
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Results and discussion
In order to establish differences in the expression of DUSP6 between normal and tumor cells, we first analyzed the mRNA levels of DUSP6 by northern blot and quantitative real-time PCR analysis in shortpassage cultures (FCN, MTR and MZC) (Calogero et al., 2004) and long-term human glioblastomas (U87MG and variants U87MGvEGFRIII, and kinasedeficient U87MGDK) (Figure 1a ). Comparing the neoplastic cells with the normal counterpart (normal human astrocytes), we observed an increased expression of DUSP6 (three-to sixfold) at baseline that increased upon mitogenic stimulation ( Figure 1a , lower panel). Consistently, gene expression studies revealed DUSP6 upregulation (mean fold changes: 3.14) in human astrocytic brain tumors compared with normal brain tissue (Petalidis et al., 2008) . All cells were serumstarved overnight and stimulated with 100 ng/ml of EGF for 3 h. Despite some fluctuation monitored, northern hybridization of non-neoplatic cells (unstimulated cultures of murine pheochromocytoma PC12 cells, mouse fibroblasts NIH-3T3 and normal human astrocytes) showed basal negligible mRNA levels and powerful induction of DUSP6 mRNA upon mitogenic stimulation ( Figure 1a , upper panel). As observed by Marchetti et al. (2005) , half-lives of DUSP6 mRNA was less than 1 h in heterologous expression systems; however, this is not the case for native DUSP6 in our system. Following this line of evidence, we quantified DUSP6 mRNA by real-time quantitative PCR in several cultures of glioblastomas ( Figure 1b) . We compared DUSP6 expression in primary astrocytoma FCN, MTR, DME, CNT, MZC and GB58 (WHO grade IV) and glioblastoma cell lines U251, T98G and U87MG, with human breast carcinoma MCF-7 cells as other neoplastic tissue (Nunes-Xavier et al., 2010) . As expected, we observed a significant increase in the percentage of major transcript at 543 bp both in unstimulated and mitogen-stimulated cells ( Figure 1b , lower panel). Interestingly, we detected two variants transcritpt encoding for different DUSP6 isoforms by PCR analysis, as described in Supplementary Figure S1 . The shorter transcript was detected as major isoform in peripheral blood lymphocytes and, to a lesser extent, in normal human astrocytes. In human glioblastomas, in contrast, the shorter transcript was only induced by mitogenic stimulation. To determine whether DUSP6 protein levels correlate with transcript levels in human glioblastoma cultures, we performed biochemical analysis by western blot. Immunoblots on cytosolic fraction showed negligible immunoreactivity of endogenous DUSP6 using commercial antibodies, as reported previously (Mark et al., 2008) . Next, we probed immunoblot membranes with a rabbit polyclonal antibody (generated by Dr Lennartson) against DUSP6, which recognizes a protein of 45 kDa ( Figure 1c) . Importantly, this antibody recognized constitutive high levels of endogenous DUSP6 as multiple bands, probably due to various phosphorylation states (Dr Lennartson's personal communication and Figure 2d ). Functional assays were performed to focus on the implication of DUSP6 overexpression in glioblastoma cancers. In vitro assays were performed with replicationdeficient adenoviral vector harboring murine sense, antisense and C293S mutant DUSP6 (Muda et al., 1996; Kim et al., 1996) . The plasmid coding for murine DUSP6 includes a COOH-terminal myc-tag cloned in pAdTRK-CMV adenoviral shuttle in BglII-EcoRV sites, which contains green fluorescent protein as a tracer (Porcellini and De Blasi, 2004) .
Growth experiments (proliferation, thymidine incorporation and cell-cycle analysis) were performed using as controls the empty vector, the antisense-DUSP6 (DUSP6-AS) vector and the mutant C293S (DUSP6-CS)-expressing vector to ensure that DUSP6 is acting on its cellular target. Antisense expression inhibited effectively concomitant expression of sense-DUSP6, as shown in Supplemetary Figure S2 . Two different glioblastoma cell lines, U87MG (p53 wild type) and U251MG (p53 mutant), were infected with empty vector and senseor antisense-DUSP6 and assayed for cell growth and (methyl-3 H) thymidine incorporation. Comparable results were obtained with two lines that showed decreased growth (41.4-fold) and thymidine incorporation (1.5-fold) compared with antisense-and control empty vector P-labeled using a 2.7-kb human DUSP6 HindIII/XhoI cDNA fragment and 18S ribosomal probe as normalized loading. All experiments were conducted on cells serum-starved overnight and stimulated with EGF, 100 ng/ml for 3 h. Northern blot (lower panel) signals were quantified by scanning densitometry using ImageJ 1.43d software (Wayne Rasband, NIH, Bethesda, MD, USA; http://rsb.info.nih.gov/ij). All experiments were carried out in triplicates and statistical significance obtained by Student's t-test. *Po0.01 as compared with the untreated normal astrocytes (Student's unpaired test); **Po0.02 as compared with the untreated sample (Student's matched pairs test). (b) Real-time quantitative PCR for DUSP6 mRNA in glioblastomas. Total mRNA (500 ng) was reverse transcribed using random primers and Superscript III (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instruction. For primers and methods, see Supplementary Materials. Human glioblastoma cultures U-251MG, U-87MG and T98G were obtained from the American Type Culture Collection (ATTC, Rochville, MD, USA) and grown according to manufacturer's instructions. U87MGDEGFR and U87MGDK were a generous gift from Dr Cavenee and Dr Furnari. Astrocytoma primary FCN, MTR, DME, CNT, MZC and GB58 cell lines (WHO grade IV) were established from tumor specimens of patients and cultured as described (Calogero et al., 2004; Ricci-Vitiani et al., 2010) . Normal human astrocytes were purchased from Cambrex Charles City, Inc. (Charles City, IA, USA) and grown according to the manufacturer's instructions. Rat PC12, mouse NHI-3T3, human MCF-7 and normal human astrocytes were used as control cells. (c) Western blot analysis of native DUSP6 protein. Constitutive high protein levels were detected in U87MG, U251 and T98G, and were stimulated with EGF for 30 min. Endogenous DUSP6 was detected on the same membrane with a 'home-made' specific antibody against DUSP6 (Lennartson's lab). Western blot analysis of phospho-ERK and total ERK was performed in the same experiment. Monoclonal anti-b-tubulin as loading control was purchased by Sigma-Aldrich (St Louis, MO, USA). (Figures 2a and b) . Phosphorylation status of ERK1/2 in these functional experiments was assayed by western blot analysis of U87MG overexpressing sense-and antisense-DUSP6. Mitogenic stimulation by EGF induced a strong phosphorylation in P-ERK1/2 that was blunted by overexpression of sense-DUSP6 adenovirus (Figure 2d ). Overexpression of wild-type DUSP6 delays progression through the cell cycle as assayed by fluorescence-activated cell sorting analysis of propidium iodide staining. U87MG cells expressing sense-DUSP6 showed an increased G1-phase compared with control and were insensitive to EGF stimulation (Figure 2c) . In vitro growth properties mediated by mutant C293S-DUSP6 overexpression in human glioblastomas are shown in Supplementary Figure S3 .
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Taking in consideration phosphatase-mediated effects on cellular morphology and adhesiveness in human glioblastomas (Tanuma et al., 2009) , we next measured adhesive properties of DUSP6-expressing cells in these cancers by in vitro analysis using clonogenic and EGFinduced detachment assays (Figure 3) . We carried out colony-formation assay with method by Porcellini et al. (1997) ; three human glioblastoma cultures, U251-MG, U87MG and the mutant U87MGDEGFR were infected and seeded at appropriate dilutions to form colonies (consist of at least 50 cells) in 2-3 weeks; then stained Figure 2 Overexpression of DUSP6 reduces growth properties in human glioblastoma. (a) Proliferation 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay was performed in 96-well flat-bottomed tissue cultures as follows. In all,1500 cells were seeded in eight replicates and infected as described in Porcellini and De Blasi (2004) and Messina et al. (2004) . All values are means±s.d. of at least three experiments in triplicate. Differences between groups were tested for statistical significance using Student's t-test. *Po0.01 as compared with the control vector-expressing cells. (b) (methyl-3 H) thymidine incorporation in U87MG-expressing sense-and antisense-DUSP6 adenoviruses. For thymidine method, see Messina et al. (2004) ; briefly, U87MG cells were infected and starved overnight; incubated with 3-5 mCi/well of (methyl-3 H) thymidine for 16 h with and without EGF (100 ng/ml). All experiments were carried out in triplicates and statistical significance obtained by Student's t-test. *Po0.01 as compared with the control vector-expressing cells; **Po0.01 as compared with DUSP6-espressing cells (Student's matched pairs test). (c) Fluorescence-activated cell sorting (FACScan) cell-cycle analysis was carried out as follows: 5 Â 10 5 of infected cells were plated in 60 mm dishes and grown in low-serum medium (0.5% fetal bovine serum) for 18 h and then stimulated with EGF 100 ng/ml in low serum. Fluorescence was determined by using the FACScan (Becton Dickinson, Franklin Lakes, NJ, USA) measuring propidium iodide staining on 40 000 events. All experiments were carried out in triplicates and statistical significance obtained by ModFit LT software (Verity Software House, Topsham, MA, USA) module. (d) Western blot analysis of recombinant sense-and antisense-DUSP6 protein and phospho-ERK status in U87MG. Ectopical overexpression of DUSP6 was detected on the same membrane with antisense-DUPS6 and control (Lennartson's antibody). Western blot analysis of phospho-ERK and total ERK was performed in the same functional experiment. Monoclonal anti-b-tubulin was used as loading control.
and counted using a stereomicroscope. Unexpectedly, cells overexpressing sense-DUSP6 had twofold more colonies than control with both high (10% fetal calf serum) and low (0.2% fetal calf serum) serum stimulation ( Figure 3a) . Moreover, phosphatase-overexpressing cells exhibited a more flattened morphology by fluorescence microscopy of green fluorescent protein-positive cells (Figure 3b ). Interestingly, we obtained similar results with U87MGDEGFR, the glioblastoma multiformes expressing the characteristic EGFR mutant (EGFRvIII, de 2-7) that does not bind ligand, signals constitutively, and is more tumorigenic than the wildtype receptor (Furnari et al., 2007) . We also examined anchorage-dependent regulation by adhesion assay. Overexpression of DUSP6 strongly inhibited cellular detachment that is normally observed after stimulation with EGF. In the mutant U87MGDEGFR glioblastoma cultures, this efffect was abrogated due to its desensitization to mitogenic stimulus. Nevertheless, DUSP6 overexpression enhanced tumor adhesiveness compared with wild-type U87MG cultures (Figure 3c ). Among human astrocytic gliomas, glioblastoma multiforme is the most common and aggressive kind of tumor characterized by high invasivity and shows very little response to chemotherapy (Maher et al., 2001) . Thus, we examined the chemosensitivity of glioblastoma-overexpressing DUSP6 by survival analysis. Cisplatin (anticancer DNA-damaging cisplatin) is a DNA-adduct-inducing anticancer frequently used to treat brain tumors (Nagane et al., 1996; Silvani et al., 2009) . We measured chemoresistance to increasing doses of drug by colorimetric 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. Mitochondrial permeability was measured in cisplatin-treated U87MG cells at 48 and 72 h, showing enhanced chemoresistance compared with controls. Indeed, depletion by antisense DUSP6-AS reversed the effect in lowering the threshold sensitivity to drug treatment (Figure 4a ). The fraction of propidium iodide-positive cells, measured by bivariate analysis on green fluorescent protein-positive cells with Then, treated with EGF (100 ng/ml) in DMEM 0.5% BSA for the indicated times. Non-adhered cells were removed by washing twice with 75 ml of 73% percoll and 0.9% NaCl, and adherent cells fixed with 50 ml of 10% glutaraldehyde in percoll and stained with 100 ml of 0.1% crystal violet, solubilized in 50 ml of 0.5% Triton X-100, and solutions were read at 570 nm in an MRX Revelation absorbance reader (Thermo Labsystems, Franklin, MA, USA). Results are expressed as mean % adhesion±s.d. from three separate experiments in triplicate, and statistical significance obtained using Wilcoxon matched test. *Po0.001 as compared with the untreated U87MG infected with the control vector (matched test); **Po0.001 to the U87MG infected with the control vector treated with EGF (unmatched test); 1Po0.02 as compared with the untreated U87MG infected with the control vector (unmatched test); 11Po0.001 to the untreated U87MG.EGFRvIII infected with the control vector (unmatched test); 111Po0.001 to the U87MG.EGFRvIII infected with the control vector treated with EGF (unmatched test).
fluorescence-activated cell sorting, is shown in Figure 4b . As anticancer DNA-damaging cisplatin induces a prolonged activation of ERK1/2, whose outcomes on cell death/cell survival are cell-type dependent (Gozdz et al., 2003; Arany et al., 2004) , we monitored ERK phosphorylation by western blot analysis during dose-response treatment of cisplatin on U87MG-expressing sense-and antisense-DUSP6 (Figure 4c ). Immunoblot analysis showed that forced expression of DUSP6 was sufficient to inhibit phosphorylation of ERK, and increasing doses of cisplatin were not able to change it at all (as reported in U87MG DUSP6-infected cells).
Finally, to evaluate tumorigenesis, xenograft injections into nude mice were carried out, showing that DUSP6-cell tumors grew significantly faster than their counterparts (Figure 4d) . Thus, overexpression of DUSP6 was per se sufficient for tumor development and hence became refractory to chemotherapy. Cisplatin-treated U87MG tumors failed in lowering tumor progression by direct cytostatic or cytotoxic effect. Notably, we observed higher tumor size (approximatively 30%) in mice inoculated with sense-DUSP6 and treated with cisplatin than in untreated control groups (Figure 4d ). Dysregulated expression of DUSP6 was observed in several types of human tumor, however, its role in tumorigenesis has not been fully clarified. The expression of DUSP6 in glioblastoma cancers was investigated to monitor possible changes in mRNA or protein expression levels. Quantification of the DUSP6 transcripts showed an increased expression in several types of human glioblastoma both primary and long-term cultures (Figure 1 ). These data were unexpected as in many cancers DUSP6 expression is downregulated, according to its putative role as tumor suppressor. Moreover, despite evidence already suggesting the existence of two transcript variants (see Gene Bank (a) Cisplatin-induced cytoxicity was measured by colorimetric 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. Cell viability of DUSP6-expressing U87MG treated with increasing doses (anticancer DNA-damaging cisplatin (CDDP), 2-10 mg/ml) was determined at 48 and 72 h. Cellular depletion of endogenous DUSP6 was obtained by overexpression of antisense-DUSP6 that was able to induce cell death mainly at higher doses of CDDP. Differences between groups were tested for statistical significance using Student's t-test. *Po0.01 as compared with the control vector treated with the same CDDP dosage; **Po0.02 as compared with the control vector treated with the same CDDP dosage. (b) Propidium iodide staining measured by fluorescence-activated cell sorting scan flow cytometer (Becton Dickinson) in U87MG-expressing sense-or antisense-DUSP6 and treated with increasing doses of cisplatin for 8 h. Differences between groups were tested for statistical significance using Student's t-test. *Po0.01 as compared with the control vector treated with the same CDDP dosage; **Po0.05 as compared with the control vector treated with the same CDDP dosage. (c) Enhanced tumor volumes measured by in vivo xenograft model. U87MG-expressing sense-DUSP6 were subcutaneously injected in immunosuppressed CD1 mice, as described in Messina et al. (2004) . Flank (heterotopic) tumors displayed increased sizes compared with control group mice in the absence/presence of cisplatin treatment. All data are the means ± s.d. of three independent experiments. The tumor weight was calculated from caliper measurements, as previously reported. Differences between groups were tested for statistical significance using non-parametric Wilcoxon matched pair Test. *Po0.001 as compared with the control vector; **Po0.001 as compared with the control vector treated with the same CDDP dosage. Figure S1) . After some experimental troubles regarding antibody specificity, we biochemically confirmed the same results obtained at mRNA level. Despite the endogenous protein scarcely described in cancer cells (Furukawa et al., 2003; Cui et al., 2006; Chan et al., 2008) , DUSP6 protein was monitored, constitutively upregulated and insensitive to acute mitogenic stimulation. Specifically, we detected a protein with the expected molecular weight (45 kDa) expressed at comparable levels in neoplastic cells as shown in Figure 1c . The mechanism leading to DUSP6 upregulation can be only hypothesized at this stage of knowledge. As stated by Bermudez et al. (2011) , upregulation of DUSP6 expression may be a way for cancer cells to maintain a level of ERK activity compatible with survival and cycle progression. In this respect, it may explain why DUSP6 expression is upregulated in many cancers harboring Ras mutations (Warmka et al., 2004 and Bloethner et al., 2005) .
Our studies focused on exacerbation of existing tumorigenic phenotypes by enforced expression of DUSP6 that we found upregulated in glioblastoma samples. We employed adenovirus-mediated expression of sense-, antisense-and catalitically inactive mutant C293S in U87MG cells for viability, colony formation, DNA synthesis and cell-cycle analysis (Figures 2 and 3 and Supplementary Figure S3 ). As expected, enforced expression of DUSP6 reduced ERK1/2 activity by inhibiting at some extent cell proliferation, as assayed by cell-cycle analysis ( 3 H-thymidine incorporation and fluorescence-activated cell sorting) but, unexpectedly, exacerbated the malignancy of glioblastoma cells. On the other hand, it may seem surprising not to observe a strong impact of DUSP6 expression on viability. These counterintuitive mild effects probably depend on cytosolic retention of ERK1/2 by DUSP6 (Murphy and Blenis, 2006; McKay and Morrison, 2007) .
Furthermore, glioblastoma malignancy relies on adhesive properties (infiltrative and radio-and chemoresistance) more than growth rates (Patterson et al., 2009) . Recently, members of the DUSPs family (DUSP26 and DUSP4) have been involved in determining the malignant phenotype of glioblastomas (Tanuma et al., 2009; Waha et al., 2010) . In both papers, downregulation correlates with the invasive phenotype but, regretfully, the DUSP26 adhesive phenotypes were measured in heterologous expression systems. In our experiments, anchorage dependence and clonogenic potential, as well as all tumorigenic parameters, were measured in several lineages of human-malignant glioblastomas. More, in other cancers, high levels of DUSP6 displayed a migratory phenotype and formed colonies in soft agar (Nunes-Xavier et al., 2010) .
Enhanced tumor growth in xenograft model recapitulates these altered adhesive properties. Interestingly, DUSP6 is a selected gene for astrocytic classification in angiogenic functional class and, recently, a potential transcriptional effect of hypoxia on the DUSP6 gene has been reported (Petalidis et al., 2008; Bermudez et al., 2011) . Moreover, inducible expression of DUSP6 specifically blunts in vivo fibroblasts growth but, in our opinion, this effect probably relies on Ha-Ras oncogene transformation (Marchetti et al., 2004) . Cisplatin treatment (both in vitro and in vivo) failed to sensitize DUSP6-overexpressing glioblastoma cells in our experiments. Remarkably, in ovarian cancer cells, resistance to cisplatin is described in DUSP6-depleted cells (Chan et al., 2008) and, in contrast, in breast cancers, DUSP6 overexpression is reported as a novel mechanism of resistance (Cui et al., 2006) . This paper describes a novel unexpected tumorpromoting function of DUSP6 and has important implication for therapeutic strategies that aim at manipulating DUSP6 expression or function for the treatment of GBM.
